CIDP study explores dual-target CAR-T cell therapy for the treatment of relapsed/refractory autoimmune disorders

Schematic illustration explaining the working principle of BCMA-CD19 bispecific CAR T cells used in current study. CD19 is the pan B cell marker but not expressed in long-lived plasma cells and BCMA is expressed in plasma blasts and long-lived plasma cells. The bispecific BCMA-CD19 CAR-T cells containing anti-BCMA single chain variable fragment (scFv) and anti-CD19 scFv in tandem, linked by GGGGS×4, could cover almost all stages of the B-cell compartment. Credit: Junnian Zheng, the Affiliated Hospital of Xuzhou Medical University Chinese scientists reveal the feasibility, tolerability, and efficacy of BCMA-CD19 Read More

Related posts:

  1. Cerebellum study identifies potential therapeutic target for management of thirst disorders
  2. Stem cell-derived therapy shows promise against treatment-resistant liver cancer
  3. Researchers pave way to target an autoimmune disease-associated gene variant
  4. Study highlights the importance of infection prevention after CAR T-cell therapy
  5. Research team identifies target protein regulating autoimmune disease lupus
  6. Researchers evaluate the benefit of dual therapy for children at risk for spinal muscular atrophy
  7. Researchers pioneer noninvasive gene therapy for brain disorders
  8. Reinvigorating exhausted immune cells reveals potential therapy target for cancer

Leave a Reply

Your email address will not be published. Required fields are marked *